Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax shares shot higher after the biotechnology company's second-quarter profit and revenue beat analyst expectations. Shares were up 15% at $7.73 on Wednesday. The stock is up 33% over the past ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics ...

The health security has long been a vaccine skeptic, promoting scientifically baseless claims that vaccines are linked to ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Novavax (NASDAQ: NVAX) ended its seventh consecutive session in the red territory after shares of the company declined 1.35% to close at $6.56 on Friday. The vaccine maker lost close to 13% in the ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...